Kenvue CEO Mongon stepping down as company continues with strategic review
Kenvue used to be a part of Johnson & Johnson. J&J announced in late 2021 that it was splitting its consumer health division from the pharmaceutical and medical device divisions in a bid to make each more nimble.
Kenvue said Monday that board member Kirk Perry will serve as interim CEO, effective immediately. Perry has served as a director since December and most recently served as CEO of Circana, a provider of market research. He spent more than 20 years at Procter & Gamble in various roles.
Kenvue also said that it is continuing to work with its strategic review committee to explore options for the company.
'The Board's strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the Company's portfolio and how it operates," Chair Larry Merlo said in a statement.
Kenvue provided some preliminary results for its fiscal second quarter. The company anticipates adjusted earnings in a range of 28 cents to 29 cents per share. Analysts polled by FactSet expect earnings of 28 cents per share.
Kenvue will report its full quarterly results on Aug. 7 and said that it will revise its full-year outlook on that date.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Trump's 'big, beautiful bill' is projected to add $3.4 trillion to the debt, budget office says
WASHINGTON — President Donald Trump's 'big, beautiful bill,' which he signed into law this month, will add $3.4 trillion to the U.S. national debt over the next decade, according to a report the nonpartisan Congressional Budget Office published Monday. The report found that the law, which Republicans passed along party lines, will also 'increase by 10 million the number of people without health insurance' by 2034. The budget office scrutinized the final version of the bill after Republicans made a series of last-minute changes to cobble together the votes needed in the Senate; it passed 51-50. That revised version subsequently passed the House on a vote of 218-214. Trump enacted it on July 4. The package extends Trump's 2017 tax cuts while providing tax deductions for tips and overtime pay for the next four years. It includes hundreds of billions of dollars in new spending for the military and to carry out Trump's mass deportation agenda. And it pays for some of that with cuts to Medicaid, SNAP benefits (which help low-income families purchase groceries) and clean energy funding. The analysis found that the law's net spending cuts of $1.1 trillion are outstripped by the $4.5 trillion in decreased revenue, compared with if the measure had not passed. Republican leaders said passing the 'big, beautiful bill' was essential to averting a tax hike at the end of this year, when much of Trump's 2017 tax law was slated to expire. Recent surveys show the bill is unpopular with Americans. Democrats are leaning heavily into attacks on the bill as a tax cut that disproportionately benefits the wealthy, paid for in part with spending cuts that harm the working class. Some Republicans and White House allies, meanwhile, are casting the bill as a tax benefit for 'working families,' highlighting the move away from taxes on tips and overtime in particular. House Speaker Mike Johnson, R-La., predicted that voters will 'reward' Republicans for the bill in the midterm elections. 'This is a bill that was written for hardworking Americans, middle- and lower-class earners in particular, and they will feel the effects of that in the economy, and they'll have higher wages and more opportunity and more economic growth, and that's a major factor in a midterm election. And the border will be secure. We'll have American energy dominance going again,' Johnson told NBC News earlier this month after it passed. Asked if he has any concerns that it will cost the GOP seats in the 2026 midterm elections, Johnson responded, 'No concerns at all. In fact, it's going to gain seats for us. We're that confident.' The CBO also found that the law, which includes changes to the Affordable Care Act, will reduce average premiums for the standard 'benchmark' ACA plan by about 0.6% in 2034. This article was originally published on
CNBC
3 hours ago
- CNBC
Trump's 'big beautiful bill' is projected to add $3.4 trillion to the debt, budget office says
President Donald Trump's "big beautiful bill," which he signed into law this month, will add $3.4 trillion to the U.S. national debt over the next decade, according to a new report published Monday by the nonpartisan Congressional Budget Office. The report found that the law, which Republicans passed along party lines, will also "increase by 10 million the number of people without health insurance" by 2034. The budget office scrutinized the final version of the bill after Republicans made a series of last-minute changes to cobble together the votes needed in the Senate; it passed by a vote of 51-50. That revised version subsequently passed the House on a vote of 218-214. Trump enacted it on July 4. The 887-page package extends Trump's 2017 tax cuts while providing tax deductions for tips and overtime pay for the next four years. It includes hundreds of billions of dollars in new spending for the military and to carry out Trump's mass deportation agenda. And it pays for some of that with cuts to Medicaid, SNAP benefits (which help low-income families purchase groceries) and clean energy funding. The analysis found that the law's net spending cuts of $1.1 trillion are outstripped by the $4.5 trillion in decreased revenue, compared to if the measure had not passed. Republican leaders said passing the "big, beautiful bill" was essential to averting a tax hike at the end of this year, when much of Trump's 2017 tax law was slated to expire. Recent surveys show the bill is unpopular with Americans. Democrats are leaning heavily into attacks on the bill as a tax cut that disproportionately benefits the wealthy, paid for in part with spending cuts that harm the working class. Some Republicans and White House allies, meanwhile, are casting the bill as a tax benefit for "working families," highlighting the move away from taxes on tips and overtime in particular. Speaker Mike Johnson, R-La., predicted that voters will "reward" Republicans for the bill in the midterm elections. "This is a bill that was written for hard working Americans, middle and lower class earners in particular, and they will feel the effects of that in the economy, and they'll have higher wages and more opportunity and more economic growth, and that's a major factor in a midterm election. And the border will be secure. We'll have American energy dominance going again," Johnson told NBC News earlier this month after it passed. Asked if he has any concerns that it will cost the GOP seats in the 2026 midterm elections, Johnson responded, "No concerns at all. In fact, it's going to gain seats for us. We're that confident." The CBO also found that the law, which includes changes to the Affordable Care Act, will reduce average premiums for the standard "benchmark" ACA plan by about 0.6% in 2034.
Yahoo
3 hours ago
- Yahoo
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
An updated edition of the June 10, 2025, article. The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025. Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generation therapies offer greater precision and improved outcomes, supporting strong market expansion. Major pharma companies — including Novartis NVS, AstraZeneca AZN, Johnson & Johnson JNJ, Pfizer PFE, AbbVie ABBV, Bristol Myers Squibb and Eli Lilly LLY — are investing heavily in cutting-edge approaches like antibody-drug conjugates (ADCs) and immuno-oncology agents. Meanwhile, smaller biotechs are driving innovation, making them attractive acquisition targets for larger players seeking to enhance their oncology pipelines. As scientific progress accelerates, the oncology market is poised for robust, long-term growth — offering compelling opportunities for investors. These factors highlight the huge potential of cancer-focused companies. With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancer space appeals to you and you're looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, Novartis and Allogene Therapeutics ALLO 3 Cancer Stocks in Focus J&J's Oncology segment comprises around 27% of its total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter of 2025 to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant plus Lazcluze, contributed significantly to growth as they witnessed strong launches. On its second-quarter conference call, J&J stated that it expects its oncology sales to reach $50 billion by the end of the decade. J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Novartis has a diverse oncology portfolio, including targeted therapies and immunotherapies. The FDA's approval of Kisqali, its CDK4/6 inhibitor for the first-line treatment of postmenopausal women with HR+/HER2 advanced or metastatic breast cancer, significantly boosted the company's oncology portfolio, with the drug now being one of the top growth drivers for the company. In particular, Kisqali has shown robust uptake in the metastatic breast cancer setting. The recent approval of a broader label for Kisqali in the United States and the EU should further fuel its sales. Kisqali recorded sales of $1.1 billion in the second quarter of 2025, up 64% year over year. Other new oncology drugs like Pluvicto (PSMA-positive metastatic castration-resistant prostate cancer) and Scemblix (chronic myeloid leukemia) also put up a stellar performance, setting the momentum for the coming years as well. Novartis' oncology sales rose 20% in constant currency terms to $4.3 billion in the second quarter of 2025. In 2024, Novartis acquired Mariana Oncology and Germany-based MorphoSys AG, which strengthened its oncology pipeline. This Zacks Rank #2 company is also investing in research to develop treatments for both common and rare cancers, focusing on precision medicine strategies. Allogene Therapeutics is focused on developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs. This Zacks Rank #2 company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — cemacabtagene ansegedleucel (cema-cel or formerly ALLO-501A) and ALLO-316 for cancer indications. Lead candidate, cema-cel, is being developed as a frontline treatment for patients with large B-cell lymphoma (LBCL). In this regard, the company has initiated the pivotal phase II ALPHA3 study to evaluate cema-cel in patients with first-line LBCL. ALLO-316, the company's first CAR T candidate for solid tumors, is being evaluated in the TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
